# US 2025/0144250 A1 · Ph-sensitive fluorophores

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144250 A1
- Document ID: US20250144250A1
- Status: Published application
- Kind: A1
- Application number: 18/730,243
- Filed: 2023-01-31
- Published: 2025-05-08
- Earliest claimed: 2022-01-31
- Assignees: The General Hospital Corporation; Georgia State University Research Foundation, Inc.
- Applicants: The General Hospital Corporation; Georgia State University Research Foundation, Inc.
- Inventors: Hak Soo Choi; Satoshi Kashiwagi; Maged Henary
- Web page: https://patentgrep.com/patent/US20250144250A1

## CPC

- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/006: {Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery}
- C09B 23/0066: {the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)}
- C09B 23/107: {four >CH- groups}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)

## Abstract

The present application provides pH-sensitive fluorophores, pharmaceutical compositions comprising pH-sensitive fluorophores, and methods for imaging of cancerous tumors comprising administering to the subject an effective amount of a compound or a pharmaceutical composition, waiting a time sufficient to allow the compound to accumulate in the cancerous tumor to be imaged, and imaging the cancerous tumor with a fluorescence imaging technique. Further provided methods of treating cancer, comprising imaging a cancerous tumor in a subject; and surgically removing the cancerous tumor from the subject.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
Y is selected from CH2, O, and S;
X1 and X2 are each independently selected from H, halogen, CN, NO2, OH, NH2, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C1-3 alkylamino, and di(C1-3 alkyl)amino;
n is 1 or 2; m is 1 or 2;
R′ and R2 are each independently selected from C1-8 alkyl and C1-8 haloalkyl, wherein said C1-8 alkyl is optionally substituted with OH, C1-3 alkoxy, C(═O)OH, SO3H, P(═O)(OH)2, NH2, C1-3 alkylamino, di(C1-3 alkyl)amino, tri(C1-3 alkyl)amino, C6-10 aryl, or 5-10 membered heteroaryl;
R3 and R4 are each independently selected from H, C1-8 alkyl and C1-8 haloalkyl, wherein said C1-8 alkyl is optionally substituted with OH, C1-3 alkoxy, C(═O)OH, SO3H, P(═O)(OH)2, NH2, C1-3 alkylamino, di(C1-3 alkyl)amino, tri(C1-3 alkyl)amino, C6-10 aryl, or 5-10 membered heteroaryl;
provided that at least one of R3 and R4 is other than H; or
R3 and R4 together with the N atom to which they are attached form a ring of formula:
wherein R5 is selected from H, C1-8 alkyl, C1-8 haloalkyl, C(═O)Cy1, and S(═O)2Cy1, wherein said C1-8 alkyl is optionally substituted with OH, C1-3 alkoxy, C(═O)OH, SO3H, P(═O)(OH)2, NH2, C1-3 alkylamino, di(C1-3 alkyl)amino, tri(C1-3 alkyl)amino, or Cy1; and
each Cy1 is independently selected from C6-10 aryl and 5-10 membered heteroaryl, each of which is optionally substituted with 1 or 2 substituents independently selected from NO2, CN, OH, C1-3 alkoxy, C(═O)OH, NH2, C1-3 alkylamino, and di(C1-3 alkyl)amino.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound has formula:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein n is 1 and m is 2, or n is 2 and m is 1.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Y is CH2.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Y is O.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Y is S.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 is C1-8 alkyl, optionally substituted with OH, C(═O)OH, SO3H, or C6-10 aryl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R2 is C1-8 alkyl, optionally substituted with OH, C(═O)OH, SO3H, or C6-10 aryl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X1 is H and X2 is H.

### Claim 10 (depends on 1)

The compound of claim 1, wherein X1 is halogen and X2 is halogen.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R3 or R4 is C1-8 alkyl, optionally substituted with OH, C(═O)OH, SO3H, or C6-10 aryl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R3 and R4 together with the N atom to which they are attached form a ring of formula:

### Claim 13 (depends on 12)

The compound of claim 12, wherein R5 is selected from H and S(═O)2Cy1.

### Claim 14 (depends on 1)

The compound of claim 1, selected from any one of the following compounds:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1, 15)

A method of imaging a cancerous tumor in a subject, the method comprising:
i) administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 15;
ii) waiting a time sufficient to allow the compound to accumulate in the cancerous tumor to be imaged; and
iii) imaging the cancerous tumor with a fluorescence imaging technique.

### Claim 17 (depends on 16)

The method of claim 16, wherein said administering comprises topically spraying the cancerous tumor or a site of an organ or tissue comprising the cancerous tumor.

### Claim 18 (depends on 16)

The method of claim 16, wherein the fluorescence imaging technique is NIR-II fluorescence imaging.

### Claim 19 (depends on 18)

The method of claim 18, wherein the time sufficient to allow the compound to accumulate in the cancerous tumor is from about 1 minute to about 24 hours.

### Claim 20 (depends on 16)

A method of treating cancer, the method comprising:
i) imaging a cancerous tumor in a subject according to the method of claim 16; and
ii) surgically removing the cancerous tumor from the subject.
